Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation

American Heart Journal

Volumn 147, Issue 5, 2004, Pages 823-827

  Zaman, Azfar G ^a   Kearney, Mark T ^a   Schecter, Clyde ^a   Worthley, Stephen G ^a   Nolan, James ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVERSION; CLINICAL ARTICLE; CONTROLLED STUDY; DEFIBRILLATION; DRUG EFFECT; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HUMAN; INCIDENCE; MALE; P WAVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT; SINUS RHYTHM; STATISTICAL SIGNIFICANCE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; CHEMOTHERAPY, ADJUVANT; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; POISSON DISTRIBUTION; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS;

EID: 3042856806     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2003.07.027     Document Type: Article

References (23)

1. Ezekowitz M.D., Levine J.A. Preventing stroke in patients with atrial fibrillation. JAMA. 281:1999;1830-1835
2. Murgatroyd F.D., Gibson S.M., Baiyan X., et al. Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation. Circulation. 99:1999;2765-2770
3. Oral H., Souza J.J., Michaud G.F., et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pre-treatment. N Engl J Med. 340:1999;1849-1854
4. Madrid A.H., Bueno M.G., Rebollo J.M., et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation a prospective and randomized study. Circulation. 106:2002;331-336
5. Zaman A.G., Alamgir F., Richens T., et al. The role of signal averaged P-wave duration and serum magnesium as a combined predictor of atrial fibrillation after elective coronary artery bypass surgery. Heart. 77:1997;527-531
6. Zaman A.G., Archbold R.A., Helft G., et al. Atrial fibrillation after coronary artery bypass surgery a model risk for stratification. Circulation. 101:2000;1403-1408
7. Guidera S.A., Steinberg J.S. The signal-averaged P-wave duration a rapid and non-invasive marker of risk of atrial fibrillation. J Am Coll Cardiol. 21:1993;1645-1651
8. Podrid P.J., Lampert S., Graboys T.B., et al. Aggravation of arrhythmia by anti-arrhythmic drugs incidence and predictors. Am J Cardiol. 59:1987;38E-44E
9. Teo K.K., Yusuf S., Furberg C.D. Effects of prophylactic anti-arrhythmic drug therapy in acute myocardial infarction an overview of results from randomized controlled trials. JAMA. 270:1993;1589-1595
10. Van den Berg M.P., Crijns H.J.G.M., van Veldhuisen D.J., et al. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail. 1:1995;355-363
11. Li D., Shinagawa K., Pang L., et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 104:2001;2608-2614
12. Pedersen O.D., Bagger H., Kober L., et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 100:1999;376-380
13. Holubarsch C., Hasenfuss G., Shmidt-Schweda S., et al. Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium an in vitro study under physiological experimental conditions. Circulation. 88:1993;1228-1237
14. Holubarsch C., Schmidt-Schweda S., Knorr A., et al. Functional significance of angiotensin receptors in human myocardium significant differences between atrial and ventricular myocardium. Eur Heart J. 15:(Suppl D):1994;88-91
15. Nakashima H., Kumagai K., Urata H., et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation. 101:2000;2612-2617
16. Goette A., Arndt M., Rocken C., et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation. 101:2000;2678-2681
17. Fukunami M., Yamada T., Ohmori M., et al. Detection of patients at risk for paroxysmal atrial fibrillation during sinus rhythm by P-wave triggered signal-averaged electrocardiogram. Circulation. 83:1991;162-169
18. Kubara I., Ikeda H., Hiraki T., et al. Dispersion of filtered P-wave duration by P-wave signal-averaged ECG mapping system its usefulness for determining efficacy of disopyramide on paroxsymal atrial fibrillation. J Cardiovasc Electrophysiol. 10:1999;670-679
19. Faggiano P., D'Aloia A., Zanelli E., et al. Contribution of left atrial pressure and dimension to signal-averaged P-wave duration in patients with chronic congestive heart failure. Am J Cardiol. 79:1997;219-222
20. Ravelli F., Allessie M. Effects of atrial dilatation on refractory period of vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation. 96:1997;1686-1695
21. Webster M.W., Fitzpatrick M.A., Nicholls M.G., et al. Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol. 56:1985;566-569
22. Brilla C.G., Matsubara L., Weber K.T. Advanced hypertensive heart disease in spontaneously hypertensive rats lisinopril-mediated regression of myocardial fibrosis. Hypertension. 28:1996;269-275
23. Giannattasio C., Cattaneo B.M., Omboni S., et al. Sympathomoderating influence of benazepril in essential hypertension. J Hypertens. 10:1992;373-378